Enliven Therapeutics, INC Form 4 insider transactions

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on July 29, 2024, under a pre-arranged trading plan.

Enliven Therapeutics CFO Benjamin Hohl executed option exercises and subsequent share sales under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, executed multiple sales of common stock on July 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Richard A. Heyman of Enliven Therapeutics, Inc. reports the sale of 1,270 shares of common stock at an average price of $24.8006.

Anish Patel, Chief Operating Officer of Enliven Therapeutics, sold shares of common stock between July 12 and July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 12,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics CFO Benjamin Hohl exercised stock options and sold shares on June 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, executed sales of common stock on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Richard A. Heyman of Enliven Therapeutics, Inc. sold 1,270 shares of common stock at a weighted average price of $21.4787, executed under a pre-arranged Rule 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on May 29, 2024, according to a Form 4 filing with the SEC.

Enliven Therapeutics CEO Samuel Kintz exercised stock options and sold shares on May 28, 2024, according to a Form 4 filing with the SEC.

Enliven Therapeutics' CFO, Benjamin Hohl, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $23.7399, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Rishi Gupta reports selling shares of Enliven Therapeutics indirectly through OrbiMed funds in transactions totaling over $29 million.

OrbiMed Advisors LLC, along with related entities, reports the sale of Enliven Therapeutics shares, while still maintaining significant ownership.

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, executed an option exercise and subsequent sale of common stock under a pre-arranged Rule 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on April 29, 2024, under a pre-arranged trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, exercised stock options and sold 12,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, exercised stock options and sold shares on April 11, 2024, according to a Form 4 filing with the SEC.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on April 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard A. Heyman, a director at Enliven Therapeutics, sold shares of the company's common stock in multiple transactions on April 11 and April 15, 2024, according to a Form 4 filing with the SEC.

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, exercised stock options and sold 20,000 shares of common stock on April 11, 2024, according to a Form 4 filing with the SEC.